Back to search results

Psycho-Spiritual Management for Advanced Cancer Patients and Caregivers

This study is testing two supportive care programs, called FFM and AC, to see how they affect the psychological well-being and quality of life for patients with advanced cancer and their family caregivers. The main goal is to see if these programs can help reduce depressive symptoms over about one year. You may be able to join if you have metastatic (stage IV) breast, thoracic, gastrointestinal, gynecological, or genitourinary cancer that hasn't progressed for at least 3 months, and you have a family caregiver willing to participate. Both you and your caregiver must be at least 18 years old. This study aims to enroll 400 participants and is currently recruiting.

Study design
This is an interventional study planning to enroll 400 participants. It is designed to be delivered via videoconferencing in both English and Spanish.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Depressive symptoms will be measured through study completion, which is an average of 1 year.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06409065

Psycho-Spiritual Management for Patients With Advanced Cancer and Their Family Caregivers

Recruiting
NAAges 18+InterventionalSupportive care
M.D. Anderson Cancer Center
~400 participants
Updated 2026-08-14 on ClinicalTrials.gov
What's tested:Meditation Program

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Depressive Symptoms
Measured over Through study completion; an average of 1 year.

Conditions

Cancer

Explore related trials

Breast CarcinomaMalignant Digestive System NeoplasmMalignant Female Reproductive System NeoplasmMalignant Genitourinary System NeoplasmSolid NeoplasmThoracic Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Kathrin Milbury, MD,PHD · PRINCIPAL_INVESTIGATOR · MD Anderson

Who to contact

Kathrin Milbury, MD,PHD
[email protected]
(713) 745-2868
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Be diagnosed with a metastatic (stage IV) breast, thoracic, gastrointestinal, gynecological, or genitourinary cancer
Be without disease progression for at least 3 months based on surveillance CT imaging
Have an ECOG performance status of ≤2
Have a family caregiver willing to participate
Be ≥18 years old
Be able to read and speak English or Spanish.
Be able to provide informed consent

What this trial measures

  • Depressive SymptomsThrough study completion; an average of 1 year.

    Participants will complete the Center for Epidemiologic Studies Depression Scale (CES-D), a 20-item self-report measure focusing on the affective component of depression, which is appropriate as patients may experience somatic symptoms due to treatment toxicities rather than depression.